



Manhattan Scientifics Engages Services of Torreya Partners

July 16, 2015

NEW YORK-- Manhattan Scientifics, Inc. (MSI) (OTCQB:MHTX) today announced the engagement of Torreya Partners and its professional services sister company, Torreya Insights. The past year has been an important one for Manhattan Scientifics with a number of notable achievements. On the nano metals side of our enterprise, we concluded an arrangement with our former industrial partner for the successful return of the licensing rights, intellectual property including all patent rights, nanotechnology manufacturing machinery, plus \$8M cash - a total exceeding \$18 million of new assets. As a result, our company has never been stronger financially. We are now able to accelerate activities in both our Senior Scientific and our Metallicum subsidiaries with minimal near term dilution.

Torreya Partners is a leading financial advisory firm that has facilitated over 100 M&A, licensing and asset sale transactions in the life sciences industry. Tim Opler of Torreya Partners indicated: "We have been very impressed by the MRX technology of Manhattan Scientifics and believe that this technology has high potential to transform the field of cancer diagnostics. We look forward to working with them to generate shareholder value in the months ahead."

See: <http://www.torreya.com/>

**About Manhattan Scientifics**

Manhattan Scientifics Inc. is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

About Senior Scientific

Senior Scientific, LLC (www.seniorscientific.com) is a New Mexico Company with research facilities located at the University of New Mexico Science and Technology Park in Albuquerque, New Mexico and longstanding relationships with the University of New Mexico Health Sciences Center, the Los Alamos National Laboratories, and the Center for Integrated Nanotechnology (CINT) at Sandia National Laboratory. The Company's focus is in the emerging field of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, and is the leader in a technology called Nanomagnetic Relaxometry ("NMR"). Its proprietary technologies and methods employ magnetic nanoparticles targeted towards cells associated with cancer and other diseases, and detect those cells tagged with magnetic nanoparticles through sophisticated magnetic sensors.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

- **Contacts:**

Manhattan Scientifics, Inc.

Marvin Maslow, 917-923-3300 marvin@mhtx.com

or

Corporate Advisory/PR:

Fastnet Advisors:

Anthony Furey, 631-665-1234

email: mtfurey@fastnetadvisors.com

or

U.S. & Canada Investor Relations:**Hawk Associates**

Frank Hawkins, 305-451-1888 f.hawkins@hawkassociates.com
